Lysosomal Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lysosomal Therapeutics Inc.
Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Merck Acquires Novel Neurodegenerative Disease Target With Calporta Buy
The deal worth up to $576m gives Merck what Calporta founding investor Avalon believes is the most advanced program targeting TRPML1, a lysosomal ion channel implicated in neurodegenerative diseases when the lysosome stops clearing debris from cells.
Biopharma Quarterly Deal-Making Statistics, Q1 2017
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
Deals Shaping The Medical Industry, February 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.